Comparative Usability Study of a Novel Auto-Injector and an Intranasal System for Naloxone Delivery.

ABSTRACT:

Introduction

The standard of care for reversal of opioid-induced respiratory depression associated with opioid overdose is injectable naloxone. This study compared the usability of two naloxone delivery devices, a naloxone auto-injector (NAI) and a naloxone intranasal delivery system (NXN), in the administration of naloxone during a simulated opioid overdose emergency. NAI (EVZIO (®) ; kaleo, Inc., Richmond, VA, USA) is a Food and Drug Administration approved single-use pre-filled auto-injector containing 0.4 mg of naloxone.

Methods

Study participants were randomly assigned to administer naloxone using NAI and NXN, sequentially. The primary endpoint was successful administration of a simulated dose of naloxone into a mannequin during a simulated opioid emergency, both before

SUBMITTER: Edwards ET 

PROVIDER: S-EPMC4470965 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature